![Jarushka Naidoo: Outcomes of patients with G2+ Pneumonitis on the PACIFIC trial JTO and JTO CRR](https://oncodaily.com/pub/uploads/2023/09/NADDOOO-2-e1724060854842-1280x721.jpeg)
Photo taken from Jarushka Naidoo/X
Mar 10, 2024, 12:08
Jarushka Naidoo: Outcomes of patients with G2+ Pneumonitis on the PACIFIC trial JTO and JTO CRR
Jarushka Naidoo shared a post on her X/Twitter page:
“Pleased to publish outcomes of patients with G2+ Pneumonitis on the PACIFIC trial JTO and JTO CRR.
- g2+ pneu 19.8% durva v 14.1% pbo
- risk factors: Asian ethnicity, IIIA dx, no induction chemo
- PFS, OS similar with/without g2+ pneu”
Source: Jarushka Naidoo/X
Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 31, 2024, 09:41